Methods
We studied 962 patients with stable CAD and free of cancer and heart
failure at baseline. NT-proBNP, galectin-3, monocyte chemoattractant
protein-1, high-sensitivity C-reactive protein, high-sensitivity cardiac
troponin I (hsTnI), and calcidiol plasma levels were assessed. The
primary outcome was new CD.